16:20 EST Vanda Pharmaceuticals (VNDA) sees FY25 revenue $210M-$250M, consensus $284.9M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year
- Vanda’s Strategic In-Licensing of Imsidolimab Signals Promising Growth in GPP Market
- AnaptysBio, Vanda announce exclusive global license agreement for Vanda
- Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
- Vanda Pharmaceuticals (VNDA) Q4 Earnings Cheat Sheet